BCAX · Bicara Therapeutics Inc.
$23.90
-0.49 (-2.01%)
At close · Aug 21
Market Cap
$1.58B
Shares
66.17M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.90
Open$24.73
Day$23.77–25.56
52W close$10.44–30.40
Avg vol 30d587K
Short int9.6M · 14.5% float · 20.4d
Short vol88%
Last earningsAug 11, 2026
DataSep 2024–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+16%
above
Price vs 50-day avg
−9%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
67%
mid-range
Momentum
relative strength
1-month return
−12%
trailing
6-month return
+36%
trailing
YTD return
+42%
this year
Relative strength
+24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
+18% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.50% of float · ▲ +3.0% MoM · 20.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
173 holders — near 2-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
EPS growth
+38%
Y/Y
Free cash flow
$-107.1M
Balance sheet
$96.7M
net cash
Quant / Vol
risk profile
Volatility
61%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+16%
Bullish
Price vs 50-day avg
−9%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
67%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $26 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
+18% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.50% of float · ▲ +3.0% MoM · 20.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
173 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $10
Now $24 · 67%
Range high $30
vs 200-day avg +16%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCAX
this stock
Bicara Therapeutics Inc.
|
$1.58B | +42.0% | — | — | 14.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCAX | -1.6% | -11.6% | +35.9% | -11.8% | +42.0% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -0.2% | -15.2% | +24.3% | -14.3% | +29.7% |
Key facts
CIK
2023658
CUSIP
055477103
13F (30d)
163 filings
160 filers
Visit website
Investor relations